Chart of Day: Recursion Pharmaceuticals (RXRX) – 1/11

Unlocking the future of biotech with artificial intelligence-powered drug discovery, Recursion Pharmaceuticals (RXRX) is a clinical stage Biotech company decoding biology to industrialize drug discovery – with a recent, massive investment from Nvidia.

Enabling the company’s mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. The company leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias.

Massive pharmaceutical companies are already applying artificial intelligence (AI) and machine learning (ML) to drug development.

RXRX last traded at $11.93 – up about 82 cents on Friday – on a volume spike to 10.8 million, as compared to daily average volume of 4.4 million shares. The company just signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction.